Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00032968 · ClinicalTrials.gov registry record · Phase 3
Buprenorphine/Naloxone Versus Clonidine for Outpatient Opiate Detoxification - 1
A Phase 3 study of Heroin Dependence and Substance Withdrawal Syndrome, sponsored by University of California, Los Angeles.
- Completed
- Registry status
- Phase 3
- Development phase
- 341
- Enrollment target
- 7
- Study locations
NCT00032968 is a Phase 3 study of Heroin Dependence and Substance Withdrawal Syndrome that has completed, run by University of California, Los Angeles. The registered enrollment target is 341 participants, above the 67-participant average among 8 other Heroin Dependence trials with a reported enrollment target (409% higher). The trial reports 7 study locations across 5 states.
The verdict
NCT00032968, a Phase 3 study of Heroin Dependence and Substance Withdrawal Syndrome, has completed, sponsored by University of California, Los Angeles.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 341 participants
- Enrollment target
- 7
- Study locations
Study Summary
The purpose of this study is to assess buprenorphine/naloxone versus clonidine for outpatient opiate detoxification.
Conditions Studied
Interventions
- DRUG Buprenorphine/naloxone
Study Locations (7)
California
- Haight-Ashbury Free Clinic - Berkeley
- Aegis Medical Systems, Inc. - Oxnard
New York
- Addiction Research and Treatment Corp - Brooklyn
- Bellevue - New York
Indiana
- Midtown Community Mental Health Center - Indianapolis
New Jersey
- UMDNJ - Robert Wood Johnson Medical School - Piscataway
Oregon
- Kaiser Permanente Northwest, Division of Addiction - Portland
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 341 participants |
| Start Date | 2001-01 |
| Est. Completion | 2002-08 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00032968
The ClinicalTrials.gov registry entry for NCT00032968 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 341 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 67-participant average among 8 other Heroin Dependence trials with a reported enrollment target (409% higher). The listed sponsor is University of California, Los Angeles, which has 897 total studies on file at ClinicalTrials.gov.
The record links to 3 conditions, with Heroin Dependence appearing as the primary indexed condition, and to 1 intervention - of which Buprenorphine/naloxone is the first listed.
NCT00032968 reports 7 study locations spanning 5 distinct geographic areas - top geographies include California, New York, Indiana.
Frequently Asked Questions
What is clinical trial NCT00032968 about?
NCT00032968 is a clinical study titled "Buprenorphine/Naloxone Versus Clonidine for Outpatient Opiate Detoxification - 1". The purpose of this study is to assess buprenorphine/naloxone versus clonidine for outpatient opiate detoxification.
What is the current status of trial NCT00032968?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 341 participants. The study started on 2001-01. Estimated completion is 2002-08.
What conditions does trial NCT00032968 study?
This clinical trial studies the following conditions: Heroin Dependence, Substance Withdrawal Syndrome, Morphine Dependence.
What interventions are being tested in trial NCT00032968?
The interventions under investigation include: Buprenorphine/naloxone (DRUG).
Who is sponsoring clinical trial NCT00032968?
This trial is sponsored by University of California, Los Angeles, which has 897 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00032968 being conducted?
This trial has 7 study locations across California, Indiana, New Jersey, New York, Oregon. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Heroin Dependence
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Reinforcing Effects of Intranasal (IN) Buprenorphine Versus Buprenorphine/Naloxone
COMPLETED · Phase 3
-
Behavioral Naltrexone Therapy for Promoting Adherence to Oral Naltrexone vs Extended Release Injectable Depot Naltrexone
COMPLETED · Phase 3
-
Study Comparing Liquid and Tablet Buprenorphine Formulations - 5
COMPLETED · Phase 3
-
Directly Administered HIV Therapy in Methadone Clinics
COMPLETED · Phase 2
-
Treatment of Opioid/Heroin Dependence: Comparison of Three Medication Dosing Regimens
COMPLETED · Phase 2
-
Opiate Dependence: Combined Naltrexone/Behavior Therapy - 1
COMPLETED · Phase 2
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.